A dedicated team of Subject-Matter Experts to build evidence, drive scientific and medical education, support value-based pricing and achieve favorable market access
Proven expertise in high-impact, high-value therapies with high unmet need across Pharma, Biotech and MedTech
Deep familiarity with first-to-market launches, especially in life-saving therapies for pediatric conditions and rare diseases
Creative and impactful evidence generation that differentiates products in crowded, competitive therapeutic areas (TAs)
Stellar track record in conducting RWE studies, successfully bringing them to publication and pull-through to support Market Access and Strategic Pricing
Clear demonstration of prior success in driving access for patients and reducing payer barriers for approval
In today’s global life sciences marketplace, the role and value of evidence is unquestionable. Novel therapies—many of which might be high-value therapeutics and/or specialty drugs—will need compelling evidence to persuade physicians to write the script and payers to provide access to label.
Pre-launch, clients need to characterize the disease landscape, identify unmet needs, create pre-launch medical education and conduct market-shaping activities.
Post-launch, therapies will need to continue to produce evidence of real-world value. Compelling evidence is especially needed in crowded, highly competitive TAs to demonstrate differential value versus other therapies.
Without high-quality evidence, commercial objectives suffer—market access can be sub-optimal, KOL advocacy can be weak and the product’s potential could be severely limited.
Trinity Evidence Strategy helps clients demonstrate the holistic value of their assets across the product lifecycle by leveraging a best-in-class methodological approach powered by technology and scientifically-driven, publication-quality primary and secondary research.
With markets growing increasingly competitive across the globe, the challenge for Med Affairs and HEOR teams is four-fold:
Trinity’s Evidence Strategy team offers a complete suite of HEOR and Med Affairs services to help differentiate the value of a product vs. the competition.
Trinity’s HEOR Core Pillars of Excellence
3 areas of deep expertise across 8 core engagement types
Evidence Planning | Evidence Generation and Execution | Scientific Dissemination
Trinity’s Evidence Strategy team helps clients design a compelling value story, demonstrate must-have evidence and drive scientific dissemination
DESIGN
Disease Landscape and Unbranded Value Story Development
The Evidence Strategy team offers a complete suite of Health Economics and Outcomes Research (HEOR) services to help differentiate the value of a product vs. the competition.
Leveraging best-in-class, scientifically driven, publication-quality primary and secondary research methods, we help our clients demonstrate the holistic value of their assets across the product lifecycle — from early clinical development all the way to launch and post-launch.
Explore the Power of aStrong Value Proposition
Providing the right evidence to payers and other key access stakeholders is essential to unlock the pricing and access potential of therapies.
Trinity’s integrated RWE and Evidence Strategy teams have collaboratively helped hundreds of clients address their most important business questions:
What are the unmet needs in the current treatment paradigm for Disease X?
What is the epidemiology of Disease X? Are there sub-types of interest?
How do I identify the right patients in the absence of ICD-9 / 10 codes?
What is the patient journey for someone suffering from Disease Y?
What are the treatment patterns, therapy use, switch / adherence behaviors?
What is the comparative effectiveness of therapies in this market / class?
What SE and AE are associated with these treatments?
What is the overall Healthcare Resource Utilization (HCRU)?
What is the holistic cost of care?
Strategically, what are the pain points, unmet needs and gaps where Treatment Z can add value?
Find out more about Trinity Real World Evidence – Helping clients navigate through the complexities of RWE analysis.
Trinity supports a broad array of high-impact scientific publications
Collaboration between HEOR and Medical Affairs helps organizations optimize value, access and patient outcomes.
An integrated approach to evidence generation is critical to optimize strategic value stories and achieve commercialization goals. A virtuous cycle of evidence generation and value delivery is woven together by insights from randomized clinical trial and real world evidence approaches to produce poignant evidence that meets decision maker needs.
Trinity’s Evidence Strategy team achieves accuracy and confidence in identifying the right patients by using the most appropriate data assets, analytics and analytical rigor to drive the evidence needed, including Trinity’s unique network of direct data access. Trinity’s integrated, tech-enabled approach allows clients to tap into dedicated, experienced HEOR and RWE teams for support:
Demonstrate product differentiation
Conduct appropriate statistical testing and comparator analyses—including matched cohort/baseline/reference
Identify compelling economic evidence to support payer engagement
Develop compelling clinical and humanistic evidence to support medical education
Which data sources have the greatest utility for each specific asset?
How—and when— can they be leveraged?
How should they be combined?
What changes in data sources will influence healthcare in the future?
Latest Industry and Scientific Publications
Demand for Real-World Evidence of Medications is Growing
Trinity’s recent white paper, titled Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR, was featured in a recent article by Formulary Watch.
Treatment preferences among health care providers in the United States in selecting disease modifying therapies for multiple sclerosis: a discrete choice experiment study
Autoimmune screening panel (ASP) is routinely ordered as a part of diagnostic work-up in people with suspected multiple sclerosis (MS). However, data on prevalence and significance of ASP seropositivity in MS is scarce.
Burden of cremophor-related paclitaxel therapy on patients with ovarian cancer: A patient focused study from the United Kingdom, Germany, and Spain.
This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life implications.
Evaluating the Clinical, Economic, and Societal Value of Rapid Diagnostic Testing in Emerging Markets: A Systematic Literature Review Assessing Infectious Diseases
This study aimed to synthesize published and other literature on the clinical, societal, and economic value of RDTs for infectious disease across Asia, Africa, and Latin America.
Evaluating the Impact of the Entry of IVD-R in the Biopharmaceutical Industry, With a Focus on Evidence Requirements and Time to Launch
This study aims to provide insight into how industry experts are preparing for IVD-R, the impact it has had and will have on research and development and evidence needed to support regulatory evaluation and product launch.
Trends in Cell and Gene Therapy Uptake and Utilization in the United States: A Real-World Analysis of the Komodo Healthcare Map™ claims Data from 2015-2021
This study aims to evaluate CGT uptake and quantify utilization patterns in the US, from 2015-2021.
Impact of COVID-19 on Telehealth Utilization: Analysis of Komodo Healthcare Map™ Claims Data
This study aimed to identify medical conditions typically treated using telehealth and quantify trends in telehealth utilization through the COVID-19 pandemic.
Generating Robust Insights to Develop a Compelling Value Story with RWE
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization […]
Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. […]
HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America
This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC […]
France Pilots Opportunity to Increase Speed to Reimbursement for Select Innovative Products
French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement […]
The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries […]
Trinity’s Evidence Strategy team features advanced degrees including multiple PhD-level experts – we consistently deliver high-quality insights and products to meet internal and external stakeholder needs.
Meet Our Evidence Strategy Experts
The team is led by an Nandini Hadker, an Economist who presents annually at ISPOR, ISPOR-EU, AMCP, AMCP-Nexus and strategic clinical conferences who has authored numerous white papers, academic research posters and peer-reviewed manuscripts in reputed journals.
Nandini Hadker is supported by Matt O’Hara and Jeff Skaar, who are also leaders in the evidence generation and HEOR space and bring deep expertise in the sphere of HEOR, evidence generation and scientific dissemination.
We use cookies to optimize our website and our service. Users can manage their cookie preferences here.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.